Testing H021 tablets for safety in healthy participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of H021 in Healthy Participants

This study is testing the safety of H021 tablets in healthy people to see how they react to different doses.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (estimated)
• Ages: 18 Years to 55 Years
• Sex: All
• Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd. (Industry-sponsored)
• Locations: 1 site (Melbourne, Victoria)
• Trial ID: NCT06627556 on ClinicalTrials.gov

What this trial studies

This Phase 1 clinical trial evaluates the safety and tolerability of H021 tablets through single and multiple ascending doses in healthy participants. The study is designed as a randomized, double-blind, placebo-controlled trial, with a food-effect evaluation included. It consists of two parts: the single ascending dose (SAD) cohorts and the multiple ascending dose (MAD) cohorts, which will be conducted sequentially with some overlap. The MAD phase will commence once safety and pharmacokinetic data from the SAD phase indicate that the doses are acceptable.

Who should consider this trial

Good fit: Ideal candidates are healthy adults aged 18 to 55 with a BMI between 18.5 and 32.0 who do not smoke and have no significant medical history.

Not a fit: Patients with significant health issues or those outside the specified age and BMI range may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to a better understanding of H021's safety profile, paving the way for future treatments for ulcerative colitis.

How similar studies have performed: While this study focuses on a specific drug, similar Phase 1 studies have successfully evaluated the safety of new treatments, indicating a potential for success.

Eligibility criteria

Inclusion Criteria:

1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), greater than and equal to (\>=) 18 and less than and equal to (\<=) 55 years of age, with body mass index (BMI) greater than (\>)18.5 and less than (\<) 32.0 kilograms per square meter (kg/m\^2).
2. Healthy as defined by:

   1. the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
   2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Female participants of non-childbearing potential must be:

   1. post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented follicle-stimulating hormone (FSH) levels \>=40 milli-international units per milliliter (mIU/mL); or
   2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or bilateral tubal occlusion) at least 3 months prior to dosing.
4. Participants must be willing not to donate sperm for 90 days or ova (egg) for 6 months after the last dose.
5. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study.
6. Able to understand the study procedures and provide signed informed consent to participate in the study.

Exclusion Criteria:

1. Any clinically significant abnormal finding at physical examination.
2. Clinically significant abnormal laboratory test results including biochemistry, hematology, urinalysis, and coagulation results, or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody, or QuantiFERON®-TB test at screening.
3. Positive pregnancy test or lactating female participant.
4. Positive urine drug screen, urine cotinine test, or alcohol breath test at screening or Day -1.
5. History of significant allergic reactions (example, anaphylactic reaction, hypersensitivity, angioedema) to any drug.
6. Clinically significant ECG abnormalities or vital signs abnormalities (systolic blood pressure lower than 90 or over 140 millimetres of mercury (mmHg), diastolic blood pressure lower than 40 or over 90 mmHg, heart rate less than 40 or over 100 beats per minute (bpm), respiratory rate less than 10 or over 22 bpm), or oxygen saturation less than 95 percent (%) oxygen at screening.
7. History of drug abuse within 1 year prior to screening as determined by the investigator.
8. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 1 month prior to screening that exceeds 10 units of alcohol per week for women and men (1 unit = 375 \[milliliter\] mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of distilled alcohol 40%).
9. History of active tuberculosis or presence of active or latent tuberculosis. Previous latent tuberculosis that has been treated and is no longer active is not exclusionary.
10. History of clinically significant opportunistic infection (example, invasive candidiasis or pneumocystis pneumonia).
11. History of serious local infection (example, cellulitis, abscess) or systemic infection (example, septicemia) within 3 months prior to screening.
12. Presence of fever (body temperature greater than (\>) 37.5 degrees Celsius (°C) (example, a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
13. Use of medications within the timeframes specified.
14. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or simultaneous participation in an investigational study involving no drug or device administration.
15. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
16. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.

Where this trial is running

Melbourne, Victoria

• Nucleus Network Ply Ltd. — Melbourne, Victoria, Australia (Recruiting)

Study contacts

• Study coordinator: Dr. Ofer Gonen

Conditions Ulcerative Colitis